The final discussed trial conducted by Javle et al. showed that an ORR of 23.1%, with median duration of response of 5.0 months and a median PFS of 7.3 months, was achieved among 108 cases of pre-treated CCA patients with FGFR2 fusion or rearrangement [118]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.